Drugs / Decoy-Resistant Interleukin-18
Decoy-Resistant Interleukin-18
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06492707 | Sep 2024 → Oct 2027 expected | acute myeloid leukemia, myelodysplastic syndrome | Fred Hutchinson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Decoy-Resistant Interleukin-18 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06492707 ↗ |
| Action | Activate | “overcomes the inhibitory effect of the IL-18BP on IL-18” NCT06492707 ↗ |
| Modality | Protein / enzyme biologic | “DR-18, a variant of the human cytokine interleukin-18” NCT06492707 ↗ |
| Route | Subcutaneous | “DR-18 subcutaneously (SC)” NCT06492707 ↗ |